Transcranial magnetic stimulation in comparison to oral Propranolol in prevention of episodic Migraine

rTMS vs Propranolol in Prevention of Episodic Migraine: A Randomized Control Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/077116

Enrollment

120

Registered

2024-11-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G438- Other migraine

Interventions

Intervention1: Repetitive transcranial magnetic stimulation: out of 2 study groups ,rTMS with predetermined frequencyâ?¢ Ten trains of 10 Hz rTMS, each train comprising of 60 pulses with an inter-trai

Eligibility

Inclusion criteria

Inclusion criteria: In this prospective follow up study, we will enroll patients with Episodic migraine as per ICHD-3 criteria and satisfying age criteria will fall between 18 years and 55 years.Patients who are already taking medications for migraine and having washout period of atleast 1 month.Patients residing within the radius of 5 kms from the centre who can come for follow up

Exclusion criteria

Exclusion criteria: Patients with major psychiatric or neurological disease (stroke, epilepsy, head injury or tumor), malignancy, liver, or kidney failure, on migraine prophylaxis in the last 2 weeks or on immunotherapy, Patients with hypertension, cardiac diseases, bronchial asthma uncontrolled diabetes, bleeding disorders, or pregnancy, any contraindication to propranolol will also be excluded. Those unwilling to give consent will be excluded.

Design outcomes

Primary

Measure	Time frame
At 3 month, clinical outcome/ response and cGRP levels will be assessed of every patient and will be correlated with headache severity, intensity, frequency and duration. The primary outcome will be â?¥ 50% reduction in headache days. Timepoint: At 3 month, clinical outcome/ response and cGRP levels will be assessed of every patient and will be correlated with headache severity, intensity, frequency and duration. The primary outcome will be â?¥ 50% reduction in headache days. The secondary outcomes will be the reduction in severity, number of abortive medications, and side effects. The exact frequency of headache, VAS score, and number of abortive medications will also be evaluated in both groups.	—

Measure

Time frame

At 3 month, clinical outcome/ response and cGRP levels will be assessed of every patient and will be correlated with headache severity, intensity, frequency and duration. The primary outcome will be â?¥ 50% reduction in headache days. Timepoint: At 3 month, clinical outcome/ response and cGRP levels will be assessed of every patient and will be correlated with headache severity, intensity, frequency and duration. The primary outcome will be â?¥ 50% reduction in headache days. The secondary outcomes will be the reduction in severity, number of abortive medications, and side effects. The exact frequency of headache, VAS score, and number of abortive medications will also be evaluated in both groups.

—

Secondary

Measure	Time frame
The secondary outcomes will be the reduction in severity, number of abortive medications, and side effects. The exact frequency of headache, VAS score, and number of abortive medications will also be evaluated in both groups. Timepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Anand Vardhan

BHU varanasi

varanand.26@gmail.com06280799087

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026